Marker Therapeutics is a clinical-stage immuno-oncology company. Co. focuses on the development of peptide and gene-based immunotherapeutics and vaccines for the treatment of cancer and metastatic disease, as well as develops DNA expression technology. Co. is developing vaccines that target candidate breast cancer(s), colorectal cancer(s), ovarian cancer(s) and non-small cell lung cancer(s). Co.'s three primary technology platforms include: a licensed vaccine for the treatment of HER2/neu+ breast cancer; a licensed vaccine for treating breast and ovarian cancers; and a wholly owned DNA expression vaccine technology (Polystart) for treating various cancers or infectious disease. We show 10 historical shares outstanding datapoints in our coverage of TPIV's shares outstanding history.
Understanding the changing numbers of TPIV shares outstanding — and
comprehending the concept of differing number of shares outstanding in general comparing companies like TPIV versus peers —
is critical for investors. Many "beginner" or "novice" investors will look at one stock trading at a price of $10 per share and another trading at
a price of $20 per share and think the latter company is worth twice as much. Of course, that is a completely meaningless comparison without also knowing how many shares outstanding there are for each of the two companies.
Furthermore, via issuance of new shares over time, or the repurchase of existing shares, the number of shares outstanding can fluctuate over the course of history.
With this page we aim to empower investors researching TPIV by allowing them to research TPIV shares outstanding history
as well as any other stock in our coverage universe. |
Video: Shares Outstanding Importance
